Plasma-SeqSensei™ Kits

Ultra-sensitive NGS liquid biopsy kit solutions

With more than 10 years of experience in liquid biopsy, Sysmex Inostics is propelling liquid biopsy solutions forward with a new next-generation sequencing-based assay: the Plasma-SeqSensei* kit.

Built on ultra-sensitive SafeSEQ technology, the new Plasma-SeqSensei RUO kit portfolio detects and identifies mutations in various genes in human circulating cell-free DNA isolated from blood plasma**.

Plasma-SeqSensei RUO kits provide narrow panels with ultra-high sensitivity down to 0.06% mutant allele fractions (MAF) and absolute limit detection of 6 mutant molecules (MM) which is important for the clinical research purpose such as response monitoring, recurrence monitoring, and minimal residual disease detection.


*Currently only available in EMEA region

**For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer

Citations

*Currently only available in EMEA region

**For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer

Kit Products

Unique Benefits


This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • Highly sensitive
    • Detects 0.06% and higher MAF with 95% certainty (in a background of 10,000 wildtype copies)
    • Determines mutant molecules (MM) down to a limit of detection of 6 (independent of real sample DNA input)


This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • Absolute quantification of samples using internal quantifier
  • Usage of UID’s (unique molecular identifiers)
    • Reduces error rate up to 100-fold to discriminate random errors and true mutations
  • Standardized workflow and high reproducibility


This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • High flexibility and efficiency
    • Processes 2–16 samples per run
    • Pools multiple PSS RUO libraries in one run to save time and sequencing costs
  • Short turnaround time
    • Takes ~2 days for 16 samples from plasma preparation to results (including sequencing time)


This chart measures the mutant allele frequency of SafeSEQ with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that SafeSEQ has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • Easy-to-use and convenient Plasma- SeqSensei Software
    • Integrates run-planning feature
    • Provides sample variant call file, including validity checks for sample results
    • Automates data analysis and generation of QC with mutation reports per sample

News & Events

The latest

Visit our resource center

Visit our resource center